PDF(Pubmed)
Abstract：
UNASSIGNED: Newer antidiabetic medications such as sodium-glucose co-transporter 2 inhibitors (SGLT2i) and glucagon-like peptide 1 receptor agonists (GLP1RA) result in weight loss in clinical trials. However, the real-world effectiveness remains unclear. The magnitude of weight change associated with antidiabetic medication using real-world data was examined.
UNASSIGNED: Patients with diabetes who initiated SGLT2i (n = 906), GLP1RA (n = 782), dipeptidyl peptidase-4 inhibitors (DPP4i, n = 1881), or sulfonylureas (n = 3255) in Geisinger Health System were identified. Outcomes were percent weight change per year and time to 5% weight loss. Propensity scores were used to account for differences across groups.
UNASSIGNED: The mean ± SD age of patients was 57.5 ± 14.1 years, 3381 (49.5%) were female, and 6450 (94.5%) had body mass index ≥25 kg/m2. Compared with sulfonylureas, newer antidiabetic medications were associated with significant weight loss (-3.2% [95% confidence interval: -3.8%, -2.6%] per year for SGLT2i; -2.9% [-3.6%, -2.3%] per year for GLP1RA; and -1.7% [-2.1%, -1.3%] per year for DPP4i). SGLT2i and GLP1RA were also associated with significant weight loss compared with DPP4i. Among patients with overweight or obesity, SGLT2i and GLP1RA users were more likely to achieve 5% weight loss compared with sulfonylureas and DPP4i.
UNASSIGNED: In real-world practice, SGLT2i and GLP1RA were associated with significant weight loss compared with sulfonylureas and DPP4i. These results may further motivate uptake of SGLT2i and GLP1RA, especially among patients who were overweight or had obesity.
UNASSIGNED: Patients with diabetes who initiated SGLT2i (n = 906), GLP1RA (n = 782), dipeptidyl peptidase-4 inhibitors (DPP4i, n = 1881), or sulfonylureas (n = 3255) in Geisinger Health System were identified. Outcomes were percent weight change per year and time to 5% weight loss. Propensity scores were used to account for differences across groups.
UNASSIGNED: The mean ± SD age of patients was 57.5 ± 14.1 years, 3381 (49.5%) were female, and 6450 (94.5%) had body mass index ≥25 kg/m2. Compared with sulfonylureas, newer antidiabetic medications were associated with significant weight loss (-3.2% [95% confidence interval: -3.8%, -2.6%] per year for SGLT2i; -2.9% [-3.6%, -2.3%] per year for GLP1RA; and -1.7% [-2.1%, -1.3%] per year for DPP4i). SGLT2i and GLP1RA were also associated with significant weight loss compared with DPP4i. Among patients with overweight or obesity, SGLT2i and GLP1RA users were more likely to achieve 5% weight loss compared with sulfonylureas and DPP4i.
UNASSIGNED: In real-world practice, SGLT2i and GLP1RA were associated with significant weight loss compared with sulfonylureas and DPP4i. These results may further motivate uptake of SGLT2i and GLP1RA, especially among patients who were overweight or had obesity.
摘要：
较新的抗糖尿病药物如钠-葡萄糖共转运蛋白2抑制剂(SGLT2i)和胰高血糖素样肽1受体激动剂(GLP1RA)在临床试验中导致体重减轻。然而,现实世界的有效性仍不清楚。使用真实世界数据检查与抗糖尿病药物相关的体重变化幅度。
■启动SGLT2i（n=906）的糖尿病患者，GLP1RA（n=782），二肽基肽酶-4抑制剂（DPP4i，n=1881)，或磺酰脲类（n=3255）在Geisinger卫生系统中进行了鉴定。结果是每年的体重变化百分比和体重减轻5%的时间。倾向得分用于解释组间的差异。
■患者的平均±SD年龄为57.5±14.1岁，3381（49.5%）为女性，6450（94.5％）的体重指数≥25kg/m2。与磺酰脲类相比，新的抗糖尿病药物与显著的体重减轻相关(-3.2%[95%置信区间:-3.8%,SGLT2i每年-2.6%；-2.9%[-3.6%，GLP1RA每年-2.3%；和-1.7%[-2.1%，DPP4i每年-1.3%]。与DPP4i相比,SGLT2i和GLP1RA也与显著的体重减轻相关。在超重或肥胖患者中，与磺酰脲类和DPP4i相比，SGLT2i和GLP1RA使用者更有可能实现5%的体重减轻。
■在现实世界的实践中，与磺酰脲类和DPP4i相比，SGLT2i和GLP1RA与显着的体重减轻有关。这些结果可能进一步激发SGLT2i和GLP1RA的摄取，尤其是超重或肥胖患者。
■启动SGLT2i（n=906）的糖尿病患者，GLP1RA（n=782），二肽基肽酶-4抑制剂（DPP4i，n=1881)，或磺酰脲类（n=3255）在Geisinger卫生系统中进行了鉴定。结果是每年的体重变化百分比和体重减轻5%的时间。倾向得分用于解释组间的差异。
■患者的平均±SD年龄为57.5±14.1岁，3381（49.5%）为女性，6450（94.5％）的体重指数≥25kg/m2。与磺酰脲类相比，新的抗糖尿病药物与显著的体重减轻相关(-3.2%[95%置信区间:-3.8%,SGLT2i每年-2.6%；-2.9%[-3.6%，GLP1RA每年-2.3%；和-1.7%[-2.1%，DPP4i每年-1.3%]。与DPP4i相比,SGLT2i和GLP1RA也与显著的体重减轻相关。在超重或肥胖患者中，与磺酰脲类和DPP4i相比，SGLT2i和GLP1RA使用者更有可能实现5%的体重减轻。
■在现实世界的实践中，与磺酰脲类和DPP4i相比，SGLT2i和GLP1RA与显着的体重减轻有关。这些结果可能进一步激发SGLT2i和GLP1RA的摄取，尤其是超重或肥胖患者。
